This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Health Winners & Losers: Eli Lilly

Health stocks were down - as were the broader markets - amid the kickoff of third-quarter results.

The NASDAQ and Amex biotechnology indices were down 1.1% and 1.7%, respectively. Big biotech Amgen (AMGN - Get Report) and Biogen (BIIB - Get Report) were down 2.7% and 0.9%.

Pharmaceutical stocks fared better than their biotech cousins -- the Amex pharma index was up just 0.8%,

One component of the pharma index, Eli Lilly (LLY - Get Report) said Tuesday that it has commenced the tender offer for all outstanding shares of ImClone (IMCL) at $70 a share. The $6.5 billion deal was announced last week.

ImClone shares rose 82 cents, or 1.2%, at $67.82, while Lilly's shares fell 88 cents, or 2.4%, to $34.98 on Tuesday.

One of the first health stocks to release earnings, Johnson & Johnson (JNJ - Get Report)reported income of $3.31 billion, or $1.17 a share, on revenue of $15.9 billion. Results topped expectations of analysts surveyed by Thomson Reuters who'd pegged $1.11 a share on $15.69 billion. Shares were up $1.48, or 2.4%, at $64.14.

Elsewhere - in a few analyst actions -- Needham upped its rating for medical technology company and device maker Stryker (SYK - Get Report) to buy from hold with a $66 price target. That stock was trading up $1.33, or 2.3%, at $59.86.

Also, Cantor Fitzgerald significantly upped its price target for Sequenom (SQNM - Get Report), which is developing a non-invasive prenatal test for Down syndrome to $42 from $29. Shares added 34 cents, or 1.8%, to $19.76.

Look for earnings from Abbott Laboratories (ABT - Get Report)and St. Jude Medical (STJ - Get Report) before the market open on Wednesday. Analysts, on average, are expecting 77 cents a share on revenue of $7.35 billion for the third quarter from Abbott and 57 cents a share on $1.07 billion in revenue from St. Jude.

After the close on Wednesday, look for third quarter results from Amylin (AMLN). The Street expects Amylin to report a loss of 50 cents a share on $229 million in revenue.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
IMCL $1.18 -1.67%
ABT $45.26 0.76%
AMGN $160.91 -0.12%
BIIB $287.20 0.12%
JNJ $102.17 0.92%


Chart of I:DJI
DOW 17,817.53 +97.61 0.55%
S&P 500 2,091.24 +10.83 0.52%
NASDAQ 5,129.28 +20.6140 0.40%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs